On September 24th at 7:00pm EDT, Dr. Holly Andersen, Director of Education and Outreach at the Ronald O. Perelman Heart Institute at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, will host a live webcast exploring the advances and innovations in the treatment of cardiovascular disease. The air live on ORLive.com from the Hospital's new Ronald O. Perelman Heart Institute.
The webcast will present a wide array of recent cardiovascular developments, including the latest technological advances in left main stenting, ventricular assist devices (VADs), catheter-based approaches for the treatment of atrial fibrillation, as well as information about the PARTNER clinical trial, the world's only randomized controlled study of replacement transcatheter aortic heart valves.
"Transcatheter therapeutics is a potential game-changer in the field of valvular heart disease. Demographics tell us that over 600,000 people have aortic stenosis that isn't treatable with open surgery. The successful outcome of a PARTNER trial could mean a major improvement in quality of life for these patients," says Dr. Arash Salemi, a cardiothoracic surgeon at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and Assistant Professor of Cardiothoracic Surgery Weill Cornell Medical College.
Dr. Shalemi and other cardiovascular experts will also be available to answer live email questions during the webcast.
The webcast is being presented as part of the celebration of the Sept. 14 opening of the Ronald O. Perelman Heart Institute. Designed to function as a "medical town square," the new Institute features a patient-friendly welcome center, a clinical trials enrollment center, and an interactive education resource center with the latest medical information on heart disease.
"A core mission of the new Perelman Heart Institute is community education and outreach. Increasing everyone's understanding of heart disease will undoubtedly save lives," says Dr. Andersen, who is also Assistant Professor of Medicine at Weill Cornell Medical College.
Ablation may offer better outcomes than medication for ventricular tachycardia